David J. Vaughn, M.D.

faculty photo
GU Medical Oncology Professor
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-114
3400 Civic Center Blvd
Philadelphia, PA 19104-4283
Office: 215-349-8140
Fax: 215-662-7804
Education:
A.B. (Spanish)
Dartmouth College, 1982.
M.D. (Medicine)
Harvard Medical School, 1987.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

New Drug Development for Urologic Cancer
Cancer Survivorship

Description of Clinical Expertise

Urologic Oncology
Bladder Cancer
Prostate Cancer
Testis Cancer
Cancer Survivorship

Selected Publications

Sadigh S, J Farahani S, Shah A, Vaughn D, Lal P.: Differences in PD-L1-expressing macrophages and immune microenvironment in testicular germ cell tumors. American Journal of Clinical Pathology Dec 2019 Notes: Epub ahead of print.

Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, Emamekhoo H, Feldman DR, Geynisman DM, Hancock SL, LaGrange C, Levine EG, Longo T, Lowrance W, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Saylor P, Sircar K, Smith DC, Tzou K, Vaena D, Vaughn D, Yamoah K, Yamzon J, Johnson-Chilla A, Keller J, Pluchino LA.: Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 17(12): 1529-1554, Dec 2019.

Farazdaghi A, Vaughn DJ, Singhal S: Pulmonary metastatectomy for germ cell tumors. Annals of Thoracic and Cardiovascular Surgery Nov 2019 Notes: Epub ahead of print.

Abu Zaid M, Dinh PC, Monahan PO, Fung C, El-Charif O, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Althouse S, Ardeshir-Rouhani-Fard S, Sesso HD, Huddart R, Mushiroda T, Kubo M, Dolan ME, Einhorn LH, Fossa SD, Travis LB; Platinum Study Group: Adverse health outcomes in relationship to hypogonadism after chemotherapy: a multicenter study of testicular cancer survivors. Journal of the National Comprehensive Cancer Network 17(5): 459-468, May 2019.

Osterman CK, Babu DS, Geynisman DM, Lewis B, Somer RA, Balar AV, Zibelman MR, Guancial EA, Antinori G, Yu S, Narayan V, Guzzo TJ, Plimack ER, Vaughn DJ, Fung C, Mamtani R: Efficacy of split schedule versus conventional schedule neoadjuvant cisplatin-based chemotherapy for muscle-invasive bladder cancer. Oncologist 24(5): 688-690, May 2019.

AlDubayan SH, Pyle LC, Gamulin M, Kulis T, Moore ND, Taylor-Weiner A, Hamid AA, Reardon B, Wubbenhorst B, Godse R, Vaughn DJ, Jacobs LA, Meien S, Grgic M, Kastelan Z, Markt SC, Damrauer SM, Rader DJ, Kember RL, Loud JT, Kanetsky PA, Greene MH, Sweeney CJ, Kubisch C, Nathanson KL, Van Allen EM, Stewart DR, Lessel D; Regeneron Genetics Center (RGC) Research Team: Association of inherited pathogenic variants in Checkpoint Kinase 2 (CHEK2) with susceptibility to testicular germ cell tumors. Journal of the American Medical Association Oncology 5(4): 514-522, Apr 2019.

Trendowski MR, El Charif O, Ratain MJ, Monahan P, Mu Z, Wheeler HE, Dinh PC, Feldman DR, ArdeshirRouhaniFard S, Hamilton R, Vaughn DJ, Fung C, Kollmannsberger C, Mushiroda T, Kubo M, Hannigan R, Strathmann FG, Einhorn LH, Fossa SD, Travis LB, Dolan ME.: Clinical and genome-wide analysis of serum platinum levels after cisplatin-based chemotherapy. Clinical Cancer Research 2019 Notes: Epub ahead of print.

Feld E, Harton J, Meropol NJ, Adamson BJS, Cohen A, Parikh RB, Galsky MD, Narayan V, Christodouleas J, Vaughn DJ, Hubbard RA, Mamtani R: Effectiveness of first-line immune checkpoint blockade versus carboplatin-based chemotherapy for metastatic urothelial cancer. European Urology 2019 Notes: Epub ahead of print.

Narayan V, Vaughn DJ, Ky B.: Cardiovascular toxicities of therapy for genitourinary malignancies. Urologic Oncology 2019 Notes: Epub ahead of print.

Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de Wit R, Bajorin DF: Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of follow-up. Annals of Oncology 2019 Notes: Epub ahead of print.

back to top
Last updated: 12/13/2019
The Trustees of the University of Pennsylvania